test

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions

Ovarian Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Sarcoma | Stage I Ovarian Cancer | Stage IA Fallopian Tube Cancer | Stage IA Ovarian Cancer | Stage IA Uterine Sarcoma | Stage IB Fallopian Tube Cancer | Stage IB Ovarian Cancer | Stage IB Uterine Sarcoma | Stage IC Fallopian Tube Cancer | Stage IC Ovarian Cancer | Stage IC Uterine Sarcoma | Stage II Ovarian Cancer | Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIA Uterine Sarcoma | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIB Uterine Sarcoma | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIA Uterine Sarcoma | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIB Uterine Sarcoma | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer | Stage IIIC Uterine Sarcoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Uterine Carcinosarcoma

What is the purpose of this trial?

This randomized phase III trial studies paclitaxel and carboplatin see how well it works compared with paclitaxel and ifosfamide in treating patients with newly diagnosed persistent or recurrent uterine, ovarian, fallopian tube, or peritoneal cavity cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether paclitaxel is more effective when given with carboplatin or ifosfamide in treating patients with uterine, ovarian, fallopian tube, or peritoneal cavity cancer.



Participation Guidelines

Age:
18 Years - N/A
Gender:
Female

Click here for detailed information about who can participate in this trial.


Sponsor:
Gynecologic Oncology Group
National Cancer Institute (NCI)
Dates:
August 2009
Last Updated:
December 23, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT00954174